The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14341
Abstract: The mineralocorticoid receptor (MR) contributes to fibrosis in various tissues, and MR antagonists, like eplerenone, are used to prevent fibrosis. The role of MR antagonists in hepatic fibrosis and cirrhosis is unknown. Here, we investigated… read more here.
Keywords: receptor antagonist; cirrhosis; mineralocorticoid receptor; eplerenone ... See more keywords